Viroclinics, a Rotterdam, The Netherlands-based clinical research organization, was acquired by Parcom Capital.
The amount of the deal was not disclosed.
With the acquisition, Parcom plans to support the company’s growth ambitions, by expanding its fields of expertise and its portfolio of services.
Founded in 2001 and led by Bob van Gemen, CEO, Viroclinics Biosciences tests new vaccines and drugs in the clinical trial stages prior to their market launch. The company, which employs more than 100 experts, serves pharmaceutical development companies, producers and contract organisations that develop anti-viral drugs and vaccines globally.
For instance, Viroclinics tests around 90 percent of all anti-influenza medications developed worldwide and expects to see further growth in other fields of virology in the coming years.
With the acquisition, Gilde Healthcare Service is selling its stake in the company.